Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 15, Issue 3, Pages 327-333Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2015.996551
Keywords
Alzheimer' disease; combination therapy; collaboration; co-development; novel therapy
Categories
Funding
- Eli Lilly
- Eisai
- Avid
- Janssen
- Biogen Idec
- Merck Lilly
- Roche
- Genentech
- Alkermes
- Forest
- FORUM Pharmaceuticals
- Lundbeck
- Merck
- Novartis
- Otsuka
- Sunovion
- Takeda
- Toyama
- Vanda
- Wellcome Trust
- IMI
- Abbvie
- Bayer Healthcare
- Boehringer Ingelheim
- GSK
- Pfizer
Ask authors/readers for more resources
Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available